Clinical outcome and bromodeoxyuridine-derived proliferation indices in 75 invasive breast carcinomas
- 31 December 2000
- journal article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 26 (8) , 747-750
- https://doi.org/10.1053/ejso.2000.0997
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- EDUCATIONAL SECTION: Risk analysis in surgical oncology—Part I: concepts and toolsEuropean Journal of Surgical Oncology, 2000
- Cell production rates in human tissues and tumours and their significance. Part 1: an introduction to the techniques of measurement and their limitationsEuropean Journal of Surgical Oncology, 2000
- Prognostic and predictive value of thymidine labelling index in breast cancerBreast Cancer Research and Treatment, 1998
- MIB-1 labelling index is an independent prognostic marker in primary breast cancerBritish Journal of Cancer, 1998
- Prognostic significance of cell cycle parameters in infiltrative ductal breast carcinomaJournal of Clinical Laboratory Analysis, 1998
- Comparison of mathematical formulas used for estimation of DNA synthesis time of bromodeoxyuridine‐labelled cell populations with different proliferative characteristicsCell Proliferation, 1996
- Cell kinetics in vivo of human breast cancerBritish Journal of Surgery, 1996
- Apoptosis in the Pathogenesis and Treatment of DiseaseScience, 1995
- The histochemical evaluation of proliferation in breast carcinomas labelled in vivo with bromodeoxyuridineThe Breast, 1993
- Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2′-deoxyuridine labelling: A flow cytometric study of 75 tumoursBritish Journal of Surgery, 1992